Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study

被引：0

作者：

Yildirim, E. Caliskan ^{[1
]}

Atag, E. ^{[1
]}

Yuzugullu, E. ^{[2
]}

Unal, O. U. ^{[3
]}

Celebi, A. ^{[4
]}

Keser, M. ^{[5
]}

Uzun, M.

Keskinkilic, M. ^{[6
]}

Simsek, E. Tanrikulu ^{[7
]}

Sari, M. ^{[8
]}

Yavuzsen, T. ^{[6
]}

机构：

[1] Dokuz Eylul Univ, Dept Med Oncol, Fac Med, Izmir, Turkiye

[2] Haydarpasa Numune Educ & Res Hosp, Med Oncol, Istanbul, Turkiye

[3] Tepecik Educ & Res Hosp, Med Oncol, Izmir, Turkiye

[4] Marmara Univ Pendik Training & Res State Hosp, Dept Med Oncol, Istanbul, Turkiye

[5] Tepecik Training & Res Hosp, Med Oncol Dept, Izmir, Turkiye

[6] Dokuz Eylul Univ, Dept Med Oncol, Sch Med, Izmir, Turkiye

[7] Haydarpasa Numune Educ & Res Hosp, Med Oncol Dept, Istanbul, Turkiye

[8] Marmara Univ Pendik Training & Res State Hosp, Dept Med Oncol, Istanbul, Turkiye

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.644

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

468P

引用

页码：S378 / S378

页数：1

共 50 条

[41] Tumor-agnostic ctDNA monitoring in patients with metastatic HR+/HER2-breast cancer receiving first-line CDK4/ 6 inhibitor and endocrine therapy
Elliott, Mitchell J.
Fuentes-Antras, Jesus
Dou, Aaron
Gregorio, Nancy
Shah, Elizabeth
Van de Laar, Emily
Yalamanchili, Geethika
Drusbosky, Leylah M.
Amir, Eitan
Nadler, Michelle B.
Yu, Celeste
Berman, Hal K.
Siu, Lillian L.
Bedard, Philippe L.
Cescon, David W.
CANCER RESEARCH, 2024, 84 (06)
[42] Trends in HR plus metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2-and HER2+metastatic breast cancer
Brufsky, Adam
Kwan, Marilyn L.
Sandin, Rickard
Stergiopoulos, Stella
Karanth, Siddharth
Cha-Silva, Ashley S.
Makari, Doris
Goyal, Ravi K.
BREAST CANCER RESEARCH AND TREATMENT, 2024, 208 (02) : 223 - 235
[43] Clinical effectiveness of CDK4/6 inhibitors in HER2-low metastatic breast cancer
Zhang, Frank
Mesias, Jesus Anampa
CANCER RESEARCH, 2024, 84 (09)
[44] First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC)
Hoskins, Kent F.
Richards, Paul
Wisinski, Kari
CANCER RESEARCH, 2018, 78 (13)
[45] TREATMENT PATTERNS FOLLOWING FIRST LINE CDK4/6 INHIBITOR PROGRESSION IN HR+, HER2-METASTATIC BREAST CANCER
Behan, E.
Bansal, A.
Veenstra, D.
VALUE IN HEALTH, 2024, 27 (06) : S406 - S406
[46] HR+/HER2-metastatic Breast Cancer Increasing Data Density of CDK4/6 Inhibitors
Freye, Reimund
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 485 - 485
[47] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2-metastatic breast cancer in the United States
Goyal, Ravi K.
Holmes, Holly M.
Chen, Hua
Abughosh, Susan
Candrilli, Sean D.
Johnson, Michael L.
BREAST CANCER RESEARCH AND TREATMENT, 2023, 198 (01) : 159 - 166
[48] RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER plus breast cancer
Kindt, Charlotte K.
Ehmsen, Sidse
Traynor, Sofie
Policastro, Benedetta
Nissen, Nikoline
Jakobsen, Mie K.
Hundebol, Monique F.
Johansen, Lene E.
Bak, Martin
Arbajian, Elsa
Staaf, Johan
Ditzel, Henrik J.
Alves, Carla L.
FRONTIERS IN ONCOLOGY, 2025, 14
[49] Clinical and pathological characteristics of HR plus breast cancer with HER2 low and HER2(0) expression: exploring endocrine therapy sensitivity
Jin, Xin
Ma, Yun-Fei
Sun, Tong-Jun
Xie, Qiang
Yin, Fa-Xiang
Zhang, Li-Gong
Zhao, Yan
Zhao, Yan
TRANSLATIONAL CANCER RESEARCH, 2024, 13 (12) : 6850 - 6861
[50] CDK4/6 inhibitors for primary endocrine resistant HR-positive/ HER2-negative metastatic breast cancer: a case report
Luo, Ting
Zhu, Kunrui
Zhong, Xiaorong
He, Ping
Yan, Xi
Tian, Tinglun
TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4

← 1 2 3 4 5 →